drugset / Trial / NCT00799006
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
RandomizedCrossoverTriple-blindTreatment
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
Timeline
- Start
- 2008-11
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04620110 | Small molecule | 0.3 mg | Oral |
| Subject | PF-04620110 | Small molecule | 1 mg | Oral |
| Subject | PF-04620110 | Small molecule | 3 mg | Oral |
| Subject | PF-04620110 | Small molecule | 5 mg | Oral |
| Subject | PF-04620110 | Small molecule | 7 mg | Oral |
| Subject | PF-04620110 | Small molecule | 10 mg | Oral |
| Subject | PF-04620110 | Small molecule | 14 mg | Oral |
| Subject | PF-04620110 | Small molecule | 21 mg | Oral |